Trane Technologies Reports Strong Third Quarter Results

Trane Technologies Reports Strong Third Quarter Results

Highlights (third-quarter 2025 versus third-quarter 2024, unless otherwise noted): Record enterprise bookings of $6 billion, up 15 percent; organic bookings up 13 percent Bookings strength led by Americas Commercial HVAC, up approximately 30...

Hainan Media Tour: Opening Up to New Opportunities

Hainan Media Tour: Opening Up to New Opportunities

HAIKOU, China, Oct. 25, 2025 /PRNewswire/ -- A report from Hainan International Media Center: From Oct. 15-17, the Hainan Media Tour took journalists from over 20 domestic and international media outlets, including The Christian Science Monitor,...

Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website

Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website

SHANGHAI, Oct. 24, 2025 /PRNewswire/ -- At 15:00 Beijing Time (09:00 am Berlin Time) on October 20, the "Global Launch Event for Iza-bren (EGFR×HER3 Bispecific ADC) Nasopharyngeal Carcinoma BL-B01D1-303 Research Results" was held at the venue of the...

Green development blossoms in Shanghai

Green development blossoms in Shanghai

BEIJING, Oct. 24, 2025 /PRNewswire/ -- A news report from chinadaily.com.cn City makes significant progress in building application scenarios for eco-friendly and low-carbon advancements. [Photo/VCG] The year 2025 marks the 20th anniversary of the...

Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC

Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC

BEIJING, Oct. 22, 2025 /PRNewswire/ -- In October 2025, a partnership between Biokin—a rising star in China's innovative pharmaceutical sector—and global pharmaceutical leader BMS triggered a $250 million milestone payment. This is believed to be...

Unixell Biotech reported a case study of UX-DA001, an iPSC-derived autologous cell therapy for Parkinson Diseases at MDS Congress 2025

Unixell Biotech reported a case study of UX-DA001, an iPSC-derived autologous cell therapy for Parkinson Diseases at MDS Congress 2025

SHANGHAI, Oct. 16, 2025 /PRNewswire/ -- Unixell Biotech, a clinical-stage bitotech company focused on developing innovative cell therapies for Parkinson's disease (PD) and other neurological disorders, announced positive 6-month follow-up data from...

Four in Five iGaming Operators Faced Increased Fraud in the Past Year - Sumsub Global Report

Four in Five iGaming Operators Faced Increased Fraud in the Past Year - Sumsub Global Report

83% of iGaming operators have experienced fraud in the past year Latin America saw the steepest fraud rise (32% increase), while Africa recorded the biggest drop Deposit stage is now the most targeted part of the user journey Growth in AI-generated...

Ping An Ranks 27th on Forbes' Global 2000 List

Ping An Ranks 27th on Forbes' Global 2000 List

HONG KONG and SHANGHAI, June 13, 2025 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An", the "Company" or the "Group", HKEX: 2318; SSE: 601318) has risen two spots to rank 27th on Forbes' 2025 Global 2000 list, an...

Waterdrop Inc. Announces First Quarter 2025 Unaudited Financial Results, Net profit rises 34.2% year-on-year

Waterdrop Inc. Announces First Quarter 2025 Unaudited Financial Results, Net profit rises 34.2% year-on-year

BEIJING, June 5, 2025 /PRNewswire/ -- On June 5, 2025, Waterdrop Inc. (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, unveiled its unaudited financial results for the three...

ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma

ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma

SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • menu
    menu